A practical reference on pentapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
== Structure == Alpha 2-antiplasmin (α2AP) is a member of the serine protease inhibitor (serpin) superfamily and is structurally characterized by a central serpin domain flanked by unique N- and C-terminal extensions. The mature human α2AP protein consists of 452 amino acids, with a 12-residue N-terminus, a central serpin domain, and a C-terminal tail of approximately 55 residues. The reactive center loop, which is crucial for its inhibitory function, protrudes from the central serpin domain and contains the Arg364-Met365 peptide bond that is specifically targeted and cleaved by plasmin. There are two main circulating forms: Met-α2AP, which has methionine at the N-terminus, and Asn-α2AP, which is N-terminally shortened and starts with asparagine; the latter form constitutes about 70% of plasma α2AP and is more efficiently cross-linked to fibrin. The C-terminal region, rich in lysine residues, mediates the initial non-covalent binding to plasmin, facilitating the formation of a stable 1:1 stoichiometric complex. This structural arrangement allows α2AP to efficiently interact with plasmin and be incorporated into fibrin clots via cross-linking by factor XIIIa.
== Awards and honors == Csaba Horváth Medal of the Connecticut Separation Science Council (2001) Keene P. Dimick Award in Chromatography of the Society of Analytical Chemists of Pittsburgh (1998) Jubilee Award of the International Symposium on Capillary Chromatography (1998) Golden Diploma from Budapest Technical University (1995) Elected Honorary Member, Hungarian Chemical Society (1992) Marcel J. E. Golay Award of the International Symposium on Capillary Chromatography (1992) M. S. Tswett Medal of the Russian Chromatography Society (1991) Pioneer in the Development of Analytical Instrumentation of the first James L. Waters Symposium at the 41st PittCon (1990) National Award in Chromatography of the American Chemical Society (1985) A. J. P. Martin Gold Award of the Chromatography Discussion Group (1982) Anniversary Medal of Tartu University (Estonia, 1981) L.S. Palmer Award of the Minnesota Chromatography Forum (1980) Anniversary M.S. Tswett Chromatography Medal of the All-Union Scientific Council on Chromatography of the USSR Academy of Sciences (1979) M.S. Tswett Award in Chromatography of the International Symposium on Advances in Chromatography (1978)
An air compressor turns power (gasoline or an electrical motor) into potential energy. This potential energy is stored in a tank and forces air into the tank creating positive pressure. Normally a hose is connected to the tank and then when opened with a valve or switch air is shot out of the hose at high speeds. Bellow
The safety of a medical product concerns the medical risk to the subject, usually assessed in a clinical trial by laboratory tests (including clinical chemistry and haematology), vital signs, clinical adverse events (diseases, signs and symptoms), and other special safety tests (e.g. ECGs, ophthalmology). The tolerability of the medical product represents the degree to which overt adverse effects can be tolerated by the subject. (ICH E9) Screening trials
At Australia's federation in 1901, the Constitution section 51(xxxv) empowered the making of "laws for the peace, order, and good government of the Commonwealth with respect to... conciliation and arbitration for the prevention and settlement of industrial disputes extending beyond the limits of any one state". This was used to pass the Commonwealth Conciliation and Arbitration Act 1904 where a "dispute" would trigger federal jurisdiction between trade unions and employers, and this was meant to make strikes illegal or unnecessary, although in fact strikes remained "not uncommon". The Commonwealth Court of Conciliation and Arbitration (CCCA) could hear disputes, and make "awards" for fair wages and conditions across an industry if there was no agreement reached, or regulate any "industrial matters". With favourable governments in power, some courts were progressive, and in the landmark Harvester case the CCCA determined that the employer, Hugh Victor McKay that made harvesting machinery, was required to pay "fair and reasonable wages", or pay an excise tax on exports, under the Excise Tariff Act 1906. What was "fair and reasonable", said Higgins J depended on "the normal needs of an average employee, regarded as a human being in a civilised community", and this was to be found by imagining a hypothetical collective agreement, not individual bargaining with the "usual, but unequal, contest, the "higgling of the market" for labour, with the pressure for bread on one side and the pressure for profits on the other".
Sources: en.wikipedia.org
James Marsh was the first to apply this new science to the art of forensics. He was called by the prosecution in a murder trial to give evidence as a chemist in 1832. The defendant, John Bodle, was accused of poisoning his grandfather with arsenic-laced coffee. Marsh performed the standard test by mixing a suspected sample with hydrogen sulfide and hydrochloric acid. While he was able to detect arsenic as yellow arsenic trisulfide, when it was shown to the jury it had deteriorated, allowing the suspect to be acquitted due to reasonable doubt. Annoyed by that, Marsh developed a much better test. He combined a sample containing arsenic with sulfuric acid and arsenic-free zinc, resulting in arsine gas. The gas was ignited, and it decomposed to pure metallic arsenic, which, when passed to a cold surface, would appear as a silvery-black deposit. So sensitive was the test, known formally as the Marsh test, that it could detect as little as one-fiftieth of a milligram of arsenic. He first described this test in The Edinburgh Philosophical Journal in 1836.
=== 2012—2017: ZeniMax Media subsidiaries === Antonov also worked on Dishonored's DLC. Following this, Antonov became the visual design director for American company ZeniMax Media, meaning he worked on projects developed by ZeniMax's subsidiary developers—including Bethesda Game Studios, MachineGames, id Software, and Arkane—and made sure "the level of visual design and fiction" coming out of them was "the highest possible", Robert Purchese wrote. In 2012, a ZeniMax subsidiary named BattleCry Studios was founded in Austin, Texas, by developer Rich Vogel. Antonov worked on their planned debut release, a team-based multiplayer FPS titled BattleCry. In 2015, Bethesda Softworks, the planned publisher of BattleCry, revealed their "concerns" about the viability of the game releasing, and it was cancelled in 2017. Antonov was the additional art director of MachineGames' Wolfenstein: The New Order (2014); a visual designer of Dire Wolf Digital's The Elder Scrolls: Legends (2017); and a consultant on Bethesda Game Studios' Fallout 4 (2015), id Software's Doom (2016), and Arkane's Dishonored 2 (2016) and Prey (2017).
=== Catalase === The catalase test tests whether a microbe produces the enzyme catalase, which catalyzes the breakdown of hydrogen peroxide. Smearing a colony sample onto a glass slide and adding a solution of hydrogen peroxide (3% H2O2) will indicate whether the enzyme is present or not. Bubbling is a positive test while nothing happening is a negative result.
Peptidoglycan (PG) is a mesh-like structure containing polysaccharides cross-linked by peptide chains. Penicillin-binding proteins (DD-transpeptidases), in short PBPs, recognize the PG peptides and catalyze the cross-linking reactions. These enzymes are reported to have high specificity toward the chirality center of the amino acid backbone (D-chiral center) but relatively low specificity toward the side-chain structure. Therefore, when FDAAs are present, they are taken by PBPs for the cross-linking reactions, resulting in their incorporation into the PG peptide chains. At proper concentration, e.g. 1–2 mM, FDAAs labeling does not affect PG synthesis and cell growth because only 1%–2% of PG peptide chains are labeled with FDAA.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.